Table Info

Table 1.

Diagnostic accuracy for liver fibrosis in patients with MASLD using only XL probe

Author	Year	N	Probe	AUROC [prevelance (%)]
Author	Year	N	Probe	Stage 1	Stage 2	Stage 3	Stage 4
Friedrich-Rust et al. [19]	2010	50	XL	---	0.81 (30)	0.84 (24)	0.95 (6)
Friedrich-Rust et al. [20]	2012	43	XL	---	0.82 (n.d.)	0.84 (n.d.)	0.93 (n.d.)
Wong et al. [21]	2012	184	XL	---	0.80 (45)	0.85 (29)	0.91 (13)
Chan et al. [22]	2017	57	XL	---	0.90 (23)	0.95 (14)	0.97 (5)
Oeda et al. [23]	2020	96	XL	---	0.787 (52)	0.806 (27)	0.970 (5)
Cardoso et al. [24]	2020	81	XL	---	0.80 (19)	---	---

AUROC: area under the receiver operating characteristic curve; MASLD: metabolic associated steatotic liver disease. N: the number of patients; n.d.: not described; ---: no data. This table is adapted from Oeda et al. [25] (CC BY 4.0)

Declarations

Author contributions

MTE: Conceptualization, Data curation, Methodology, Supervision, Visualization, Writing—review & editing. MHH: Conceptualization, Formal analysis, Visualization, Writing—review & editing. AAE: Formal analysis, Visualization, Writing—review & editing. HMAT: Methodology, Manuscript administration, Software, Writing—review & editing. YAA: Software, Validation, Writing—review & editing. GME: Data curation, Supervision, Writing—review & editing. EAT: Methodology, Validation, Writing—review & editing. MDE: Data curation, Supervision, Validation, Writing—review & editing.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

All datasets for this study are included in the manuscript and reference articles.

Funding

Not applicable.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Farrell GC. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region? J Gastroenterol Hepatol. 2003;18:124–38. [DOI] [PubMed]

Masarone M, Federico A, Abenavoli L, Loguercio C, Persico M. Non alcoholic fatty liver: epidemiology and natural history. Rev Recent Clin Trials. 2014;9:126–33. [DOI] [PubMed]

Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686–90. [DOI] [PubMed]

Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011;332:1519–23. [DOI] [PubMed] [PMC]

Hsu CS, Kao JH. Non-alcoholic fatty liver disease: an emerging liver disease in Taiwan. J Formos Med Assoc. 2012;111:527–35. [DOI] [PubMed]

Liu B, Du Y, Wu Y, Snetselaar LG, Wallace RB, Bao W. Trends in obesity and adiposity measures by race or ethnicity among adults in the United States 2011-18: population based study. BMJ. 2021;372:n365. [DOI] [PubMed] [PMC]

Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23:8263–76. [DOI] [PubMed] [PMC]

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84. [DOI] [PubMed]

Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg. 2005;15:310–5. [DOI] [PubMed]

10.

Ward ZJ, Bleich SN, Cradock AL, Barrett JL, Giles CM, Flax C, et al. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. N Engl J Med. 2019;381:2440–50. [DOI] [PubMed]

11.

Zelber-Sagi S, Shoham D, Zvibel I, Abu-Abeid S, Shibolet O, Fishman S. Predictors for advanced fibrosis in morbidly obese non-alcoholic fatty liver patients. World J Hepatol. 2017;9:91–8. [DOI] [PubMed] [PMC]

12.

Zhang X, Wong GL, Wong VW. Application of transient elastography in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2020;26:128–41. [DOI] [PubMed] [PMC]

13.

Yoneda M, Fujita K, Inamori M, Nakajima A, Tamano M, Hiriishi H. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut. 2007;56:1330–1. [DOI] [PubMed] [PMC]

14.

Pestana L, Swain J, Dierkhising R, Kendrick ML, Kamath PS, Watt KD. Bariatric surgery in patients with cirrhosis with and without portal hypertension: a single-center experience. Mayo Clin Proc. 2015;90:209–15. [DOI] [PubMed]

15.

Ng CH, Chan KE, Chin YH, Zeng RW, Tsai PC, Lim WH, et al. The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2022;28:565–74. [DOI] [PubMed] [PMC]

16.

Li W, Ng CH, Quek J, Chan KE, Tan C, Zeng RW, et al. The growing prevalence of nonalcoholic fatty liver disease (NAFLD), determined by fatty liver index, amongst young adults in the United States. A 20-year experience. Metab Target Organ Damage. 2022;2:19. [DOI]

17.

Tsatsoulis A, Paschou SA. Metabolically Healthy Obesity: Criteria, Epidemiology, Controversies, and Consequences. Curr Obes Rep. 2020;9:109–20. [DOI] [PubMed]

18.

Chang Y, Jung HS, Cho J, Zhang Y, Yun KE, Lazo M, et al. Metabolically Healthy Obesity and the Development of Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2016;111:1133–40. [DOI] [PubMed]

19.

Friedrich-Rust M, Hadji-Hosseini H, Kriener S, Herrmann E, Sircar I, Kau A, et al. Transient elastography with a new probe for obese patients for non-invasive staging of non-alcoholic steatohepatitis. Eur Radiol. 2010;20:2390–6. [DOI] [PubMed]

20.

Friedrich-Rust M, Romen D, Vermehren J, Kriener S, Sadet D, Herrmann E, et al. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. Eur J Radiol. 2012;81:e325–31. [DOI] [PubMed]

21.

Wong VW, Vergniol J, Wong GL, Foucher J, Chan AW, Chermak F, et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2012;107:1862–71. [DOI] [PubMed]

22.

Chan WK, Nik Mustapha NR, Wong GL, Wong VW, Mahadeva S. Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population. United European Gastroenterol J. 2017;5:76–85. [DOI] [PubMed] [PMC]

23.

Oeda S, Takahashi H, Imajo K, Seko Y, Ogawa Y, Moriguchi M, et al. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan^® M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study. J Gastroenterol. 2020;55:428–40. [DOI] [PubMed]

24.

Cardoso AC, Cravo C, Calçado FL, Rezende G, Campos CFF, Neto JMA, et al. The performance of M and XL probes of FibroScan for the diagnosis of steatosis and fibrosis on a Brazilian nonalcoholic fatty liver disease cohort. Eur J Gastroenterol Hepatol. 2020;32:231–8. [DOI] [PubMed]

25.

Oeda S, Tanaka K, Oshima A, Matsumoto Y, Sueoka E, Takahashi H. Diagnostic Accuracy of FibroScan and Factors Affecting Measurements. Diagnostics (Basel). 2020;10:940. [DOI] [PubMed] [PMC]

26.

Wong VW, Adams LA, de Lédinghen V, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15:461–78. [DOI] [PubMed]

27.

Lee TH, Han SH, Yang JD, Kim D, Ahmed M. Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: An Enhanced Model of BARD Score. Gut Liver. 2013;7:323–8. [DOI] [PubMed] [PMC]

28.

Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5:362–73. [DOI] [PubMed] [PMC]

29.

Kao WY, Chang IW, Chen CL, Su CW, Fang SU, Tang JH, et al. Fibroscan-Based Score to Predict Significant Liver Fibrosis in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease. Obes Surg. 2020;30:1249–57. [DOI] [PubMed]

30.

Ali AH, Al Juboori A, Petroski GF, Diaz-Arias AA, Syed-Abdul MM, Wheeler AA, et al. The Utility and Diagnostic Accuracy of Transient Elastography in Adults with Morbid Obesity: A Prospective Study. J Clin Med. 2022;11:1201. [DOI] [PubMed] [PMC]

31.

Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;156:1264–81.e4. [DOI] [PubMed] [PMC]

32.

Venkatesh SK, Yin M, Ehman RL. Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J Magn Reson Imaging. 2013;37:544–55. [DOI] [PubMed] [PMC]

33.

Honda Y, Yoneda M, Imajo K, Nakajima A. Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2020;21:4039. [DOI] [PubMed] [PMC]

34.

Hsu C, Caussy C, Imajo K, Chen J, Singh S, Kaulback K, et al. Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants. Clin Gastroenterol Hepatol. 2019;17:630–7.e8. [DOI] [PubMed] [PMC]

35.

Imajo K, Honda Y, Kobayashi T, Nagai K, Ozaki A, Iwaki M, et al. Direct Comparison of US and MR Elastography for Staging Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2022;20:908–17.e11. [DOI] [PubMed]

36.

Serai SD, Dillman JR, Trout AT. Spin-echo Echo-planar Imaging MR Elastography versus Gradient-echo MR Elastography for Assessment of Liver Stiffness in Children and Young Adults Suspected of Having Liver Disease. Radiology. 2017;282:761–70. [DOI] [PubMed]

37.

Trout AT, Anupindi SA, Gee MS, Khanna G, Xanthakos SA, Serai SD, et al. Normal Liver Stiffness Measured with MR Elastography in Children. Radiology. 2020;297:663–9. [DOI] [PubMed] [PMC]

38.

Trout AT, Sheridan RM, Serai SD, Xanthakos SA, Su W, Zhang B, et al. Diagnostic Performance of MR Elastography for Liver Fibrosis in Children and Young Adults with a Spectrum of Liver Diseases. Radiology. 2018;287:824–32. [DOI] [PubMed]

39.

Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology. 2011;259:749–56. [DOI] [PubMed] [PMC]

40.

Costa-Silva L, Ferolla SM, Lima AS, Vidigal PVT, Ferrari TCA. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease. Eur J Radiol. 2018;98:82–9. [DOI] [PubMed]

41.

Li F, Yuan R, Zhang J, Su B, Qi X. Advances in nanotechnology for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease. Asian J Pharm Sci. 2025;20:101025. [DOI] [PubMed] [PMC]

42.

Balachandran YL, Wang W, Yang H, Tong H, Wang L, Liu F, et al. Heterogeneous Iron Oxide/Dysprosium Oxide Nanoparticles Target Liver for Precise Magnetic Resonance Imaging of Liver Fibrosis. ACS Nano. 2022;16:5647–59. [DOI] [PubMed]

43.

Wu S, Xu T, Gao J, Zhang Q, Huang Y, Liu Z, et al. Non-invasive diagnosis of liver fibrosis via MRI using targeted gadolinium-based nanoparticles. Eur J Nucl Med Mol Imaging. 2024;52:48–61. [DOI] [PubMed]

44.

Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6:6. [DOI] [PubMed] [PMC]

45.

Dincses E, Yilmaz Y. Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2015;27:1149–53. [DOI] [PubMed]

46.

Rios RS, Zheng KI, Targher G, Byrne CD, Zheng MH. Non-invasive fibrosis assessment in non-alcoholic fatty liver disease. Chin Med J (Engl). 2020;133:2743–5. [DOI] [PubMed] [PMC]

47.

Sasso M, Audière S, Kemgang A, Gaouar F, Corpechot C, Chazouillères O, et al. Liver Steatosis Assessed by Controlled Attenuation Parameter (CAP) Measured with the XL Probe of the FibroScan: A Pilot Study Assessing Diagnostic Accuracy. Ultrasound Med Biol. 2016;42:92–103. [DOI] [PubMed]

48.

Wong GL, Vergniol J, Lo P, Wai-Sun Wong V, Foucher J, Le Bail B, et al. Non-invasive assessment of liver fibrosis with transient elastography (FibroScan®): applying the cut-offs of M probe to XL probe. Ann Hepatol. 2013;12:570–80. [PubMed]

49.

Şirli R, Sporea I, Deleanu A, Culcea L, Szilaski M, Popescu A, et al. Comparison between the M and XL probes for liver fibrosis assessment by transient elastography. Med Ultrason. 2014;16:119–22. [DOI] [PubMed]

50.

Myers RP, Pomier-Layrargues G, Kirsch R, Pollett A, Duarte-Rojo A, Wong D, et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology. 2012;55:199–208. [DOI] [PubMed]

51.

Yang A, Nguyen M, Ju I, Brancatisano A, Ryan B, van der Poorten D. Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery. Sci Rep. 2021;11:14006. [DOI] [PubMed] [PMC]

52.

Naveau S, Lamouri K, Pourcher G, Njiké-Nakseu M, Ferretti S, Courie R, et al. The diagnostic accuracy of transient elastography for the diagnosis of liver fibrosis in bariatric surgery candidates with suspected NAFLD. Obes Surg. 2014;24:1693–701. [DOI] [PubMed]

53.

Puthenpura MM, Patel V, Fam J, Katz L, Tichansky DS, Myers S. The Use of Transient Elastography Technology in the Bariatric Patient: a Review of the Literature. Obes Surg. 2020;30:5108–16. [DOI] [PubMed]

54.

Berger A, Shili S, Zuberbuhler F, Hiriart JB, Lannes A, Chermak F, et al. Liver Stiffness Measurement With FibroScan: Use the Right Probe in the Right Conditions! Clin Transl Gastroenterol. 2019;10:e00023. [DOI] [PubMed] [PMC]

55.

Agarwal L, Aggarwal S, Shalimar, Yadav R, Dattagupta S, Garg H, et al. Bariatric Surgery in Nonalcoholic Fatty Liver Disease (NAFLD): Impact Assessment Using Paired Liver Biopsy and Fibroscan. Obes Surg. 2021;31:617–26. [DOI] [PubMed]

56.

Garg H, Aggarwal S, Shalimar, Yadav R, Datta Gupta S, Agarwal L, et al. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients. Surg Obes Relat Dis. 2018;14:81–91. [DOI] [PubMed]

57.

Lucidarme D, Foucher J, Le Bail B, Vergniol J, Castera L, Duburque C, et al. Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology. 2009;49:1083–9. [DOI] [PubMed]

58.

Boursier J, Zarski JP, de Ledinghen V, Rousselet MC, Sturm N, Lebail B, et al.; Multicentric Group from ANRS/HC/EP23 FIBROSTAR Studies. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology. 2013;57:1182–91. [DOI] [PubMed]

59.

Giuffrè M, Colecchia A, Crocè LS. Elastography: where are we now? Minerva Gastroenterol (Torino). 2021;67:109–11. [DOI] [PubMed]

60.

Durango E, Dietrich C, Seitz HK, Kunz CU, Pomier-Layrargues GT, Duarte-Rojo A, et al. Direct comparison of the FibroScan XL and M probes for assessment of liver fibrosis in obese and nonobese patients. Hepat Med. 2013;5:43–52. [DOI] [PubMed] [PMC]

61.

Giuffrè M, Giuricin M, Bonazza D, Rosso N, Giraudi PJ, Masutti F, et al. Optimization of Point-Shear Wave Elastography by Skin-to-Liver Distance to Assess Liver Fibrosis in Patients Undergoing Bariatric Surgery. Diagnostics (Basel). 2020;10:795. [DOI] [PubMed] [PMC]

62.

Mederacke I, Wursthorn K, Kirschner J, Rifai K, Manns MP, Wedemeyer H, et al. Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. Liver Int. 2009;29:1500–6. [DOI] [PubMed]

63.

Berzigotti A, De Gottardi A, Vukotic R, Siramolpiwat S, Abraldes JG, García-Pagan JC, et al. Effect of meal ingestion on liver stiffness in patients with cirrhosis and portal hypertension. PLoS One. 2013;8:e58742. [DOI] [PubMed] [PMC]

64.

Arena U, Lupsor Platon M, Stasi C, Moscarella S, Assarat A, Bedogni G, et al. Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. Hepatology. 2013;58:65–72. [DOI] [PubMed]

65.

Mueller S, Sandrin L. Liver stiffness: a novel parameter for the diagnosis of liver disease. Hepat Med. 2010;2:49–67. [DOI] [PubMed] [PMC]

66.

Guha IN, Myers RP, Patel K, Talwalkar JA. Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve? Hepatology. 2011;54:1454–62. [DOI] [PubMed]

67.

de Lédinghen V, Wong VW, Vergniol J, Wong GL, Foucher J, Chu SH, et al. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan^®. J Hepatol. 2012;56:833–9. [DOI] [PubMed]

68.

Wan T, Köhn N, Kröll D, Berzigotti A. Applicability and Results of Liver Stiffness Measurement and Controlled Attenuation Parameter Using XL Probe for Metabolic-Associated Fatty Liver Disease in Candidates to Bariatric Surgery. A Single-Center Observational Study. Obes Surg. 2021;31:702–11. [DOI] [PubMed]

69.

Weiss J, Rau M, Meertens J, Hering I, Reichert L, Kudlich T, et al. Feasibility of liver stiffness measurement in morbidly obese patients undergoing bariatric surgery using XL probe. Scand J Gastroenterol. 2016;51:1263–8. [DOI] [PubMed]

70.

de Barros F, Setúbal S, Martinho JM, Leite NC, Guaraná T, Monteiro ABS, et al. The Correlation Between Obesity-Related Diseases and Non-alcoholic Fatty Liver Disease in Women in the Pre-operative Evaluation for Bariatric Surgery Assessed by Transient Hepatic Elastography. Obes Surg. 2016;26:2089–97. [DOI] [PubMed]

71.

Karlas T, Dietrich A, Peter V, Wittekind C, Lichtinghagen R, Garnov N, et al. Evaluation of Transient Elastography, Acoustic Radiation Force Impulse Imaging (ARFI), and Enhanced Liver Function (ELF) Score for Detection of Fibrosis in Morbidly Obese Patients. PLoS One. 2015;10:e0141649. [DOI] [PubMed] [PMC]

72.

European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237–64. [DOI] [PubMed]

73.

Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343–50. [DOI] [PubMed]

74.

Macek P, Biskup M, Terek-Derszniak M, Krol H, Smok-Kalwat J, Gozdz S, et al. Optimal cut-off values for anthropometric measures of obesity in screening for cardiometabolic disorders in adults. Sci Rep. 2020;10:11253. [DOI] [PubMed] [PMC]

75.

Baek J, Poul SS, Basavarajappa L, Reddy S, Tai H, Hoyt K, et al. Clusters of Ultrasound Scattering Parameters for the Classification of Steatotic and Normal Livers. Ultrasound Med Biol. 2021;47:3014–27. [DOI] [PubMed] [PMC]

76.

Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. Hepatol Commun. 2017;2:48–57. [DOI] [PubMed] [PMC]

77.

Eilenberg M, Munda P, Stift J, Langer FB, Prager G, Trauner M, et al. Accuracy of non-invasive liver stiffness measurement and steatosis quantification in patients with severe and morbid obesity. Hepatobiliary Surg Nutr. 2021;10:610–22. [DOI] [PubMed] [PMC]

78.

Lim JK, Flamm SL, Singh S, Falck-Ytter YT; Clinical Guidelines Committee of the American Gastroenterological Association. American Gastroenterological Association Institute Guideline on the Role of Elastography in the Evaluation of Liver Fibrosis. Gastroenterology. 2017;152:1536–43. [DOI] [PubMed]

79.

Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S. Transient elastography (FibroScan^®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? World J Gastroenterol. 2016;22:7236–51. [DOI] [PubMed] [PMC]